Our list from march of the possible achievements in 2019, looks like CytoDyn might hit 90-95% on this list. But the big three, the share price moving milestones imo, in 2019 are still coming: BLA Complete Submissive, Partnership, Mono Pivotal Approval

-CMO: $500M product for 2020 with delayed payment
-Rolling BLA Review HIV Combo Part 1 Submission
-Monotherapy Pivotal Phase 3 Trial IND Submission
-Monotherapy Pivotal Phase 3 Trial Approval
-TNBC Trial: First Patient Injected
-TNBC Trial: ODD and FTD Approval, Preliminary CTC numbers/trial data
-GvHD Phase 2 Trial: First Patient Injected
-Animal Preclinical Trials Preliminary Data Melanoma, Pancreatic, Breast, Prostate, Colon, Lung, Liver, and Stomach Cancer
-Colon Cancer Phase 2 Trial IND Submission
-safety data on 700 mg complete for BLA
-BLA Complete Submission
-Prostate Cancer Test 510(k) filing
-GvHD Interim Results
-Colon Cancer ODD Approval
-Prognostic Prostate Cancer Test Licensing
-Multiple Sclerosis Phase 2 IND Submission
-NASH, Rheumatoid Arthritis, Lupus Animal Studies
-Non-dilutive financing licensing/partnerships announcements